LANSING, Mich. (Michigan News Source) — Michigan is trimming its Medicaid spending, and its waistline coverage.

Under the new bipartisan budget, the state will restrict access to GLP-1 weight-loss drugs like Wegovy and Zepbound to only those who are morbidly obese, slashing pharmaceutical appropriations by $240 million.

MORE NEWS: Ann Arbor Asks Contractors About Their Race, Sexual Orientation and Equity Policies

Drugs such as Ozempic and Mounjaro will still be covered for Type 2 diabetes, cardiovascular disease, and sleep apnea, but not for general weight loss. State officials say the change, effective Jan. 1, is a cost-control move after GLP-1 use among Medicaid patients jumped to 90,000 last year.

“It’s this amazing clinical breakthrough, particularly for patient populations that … are most impacted by obesity-related conditions like diabetes and obesity-related cancers and heart disease,” Dr. Mark Fendrick of the University of Michigan told Bridge Michigan.

Michigan had been among just 16 states offering Medicaid coverage for GLP-1 weight-loss drugs, but the state says beneficiaries will receive notice before the new limits begin.